Abstract
Mitotane is considered to be the drug of choice for patients with inoperable, recurrent and metastatic adrenocortical carcinoma, although a favourable effect of this drug on survival has never been documented. We evaluated the efficacy of mitotane treatment of 96 patients with adrenocortical carcinoma followed up in our department between 1959 and 1992. Complete tumour resection was the goal of the initial treatment. Mitotane treatment was classified according to serum trough concentrations on maintenance therapy: low (< 14 mg l-1) or high (> or = 14 mg l-1). Total tumour resection was feasible in 47 patients (49%), and subtotal resection was performed in 37 patients (39%). Patients who underwent total tumour resection survived significantly longer than those who did not (P < 0.001). Adjuvant mitotane therapy (n = 11) did not influence survival after total resection. Sixty-two patients were given mitotane treatment at some time during their illness, only 30 of whom reached high maintenance serum levels. Mitotane treatment with high serum levels had an independently favourable influence on patient survival, using univariate (P < 0.01) and multivariate analysis (P = 0.01). Mitotane treatment resulting in low serum levels was tantamount to not giving mitotane at all. We conclude that mitotane treatment in adrenocortical carcinoma is effective only when high serum levels can be achieved.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haak, H., Hermans, J., van de Velde, C. et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69, 947–951 (1994). https://doi.org/10.1038/bjc.1994.183
Issue Date:
DOI: https://doi.org/10.1038/bjc.1994.183
This article is cited by
-
EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity
Discover Oncology (2022)
-
Mitotane in adrenocortical carcinoma: a profile of its use
Drugs & Therapy Perspectives (2022)
-
The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging
European Journal of Drug Metabolism and Pharmacokinetics (2021)
-
Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors
Hormones and Cancer (2018)
-
Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide
Hormones and Cancer (2016)